Pollak M
Department of Medicine, McGill University, Montreal, Canada.
Yale J Biol Med. 1997 Sep-Dec;70(5-6):535-9.
Existing treatments for breast cancer are helpful for many patients, but treatment failure remains a common event, and there is a strong clinical need to improve upon current therapies. Somatostatin analogues have been evaluated for antineoplastic activity in model systems over the past decade, and encouraging results have been obtained (reviewed in [1, 2]). This has led to suggestions to test these agents clinically in the treatment of breast cancer patients, and a program of clinical trials has recently been initiated. This review will describe aspects of research in this area.
现有的乳腺癌治疗方法对许多患者有帮助,但治疗失败仍是常见情况,临床上迫切需要改进当前疗法。在过去十年中,已在模型系统中评估了生长抑素类似物的抗肿瘤活性,并取得了令人鼓舞的结果(见[1, 2]综述)。这促使人们建议在乳腺癌患者的临床治疗中测试这些药物,最近已启动了一项临床试验计划。本综述将描述该领域的研究情况。